All In Biotech

NDA 021192 · Sandoz

Lescol Xl

Fluvastatin Sodium · Oral

Last checked: Nov 19, 2026Latest source record: Nov 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Oct 6, 2000

Approved uses

4

Original approval plus efficacy supplements

Registered trials

67

15 Phase 3, 4 recruiting

FAERS reports

4,471

3,641 serious, 462 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2024.

Fluvastatin sodium extended-release tablets are indicated: • To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg of fluvastatin daily. Fluvastatin sodium extended-release tablets are indicated ( 1 ): • To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg

Mechanism: Fluvastatin is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LESCOL XL · FLUVASTATIN SODIUM EQ 80MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluvastatin" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea319
  • myalgia317
  • dizziness298
  • fatigue280
  • diarrhoea255
  • drug ineffective253
  • dyspnoea250
  • asthenia243
  • myocardial infarction221
  • fall211
  • vomiting207
  • arthralgia201

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004359
2005422
2006355
2007238
2008232
2009257
2010259
2011351
2012254
2013165
2014179
2015192
2016182
2017145
2018167
2019126
2020117
2021132
2022108
202364
202493
202540
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 27, 2026

    Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jan 27, 2026

    Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jan 27, 2026

    Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lescol XL (Fluvastatin Sodium)

2024 spending

$527K

Beneficiaries

165

616 claims

Per beneficiary

$3,195

$12.67 per unit

View as table
YearSpending
2020$888,261
2021$962,166
2022$865,926
2023$722,048
2024$527,126

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 455 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.